AR089839A1 - Composicion farmaceutica que combina cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil)-naftalen-2-il-metil]-amonio y al menos un agente activo antiinflamatorio para su uso en tratamiento de distrofia muscular - Google Patents

Composicion farmaceutica que combina cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil)-naftalen-2-il-metil]-amonio y al menos un agente activo antiinflamatorio para su uso en tratamiento de distrofia muscular

Info

Publication number
AR089839A1
AR089839A1 ARP130100264A ARP130100264A AR089839A1 AR 089839 A1 AR089839 A1 AR 089839A1 AR P130100264 A ARP130100264 A AR P130100264A AR P130100264 A ARP130100264 A AR P130100264A AR 089839 A1 AR089839 A1 AR 089839A1
Authority
AR
Argentina
Prior art keywords
methyl
pharmaceutical composition
hydroxicarbamoil
distration
carbamoiloxi
Prior art date
Application number
ARP130100264A
Other languages
English (en)
Inventor
Saccone Valentina
Mascagni Paolo
Lorenzo Puri Pier
Consalvi Silvia
Original Assignee
Italfarmaco Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco Spa filed Critical Italfarmaco Spa
Publication of AR089839A1 publication Critical patent/AR089839A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica caracterizada porque comprende la combinación de cloruro de dietil-[6-(4-hidroxicarbamoil-fenilcarbamoiloximetil)-naftalen-2-il-metil]-amonio o las sales y/o solvatos del mismo aceptables para uso farmacéutico, y al menos un agente activo antiinflamatorio. Reivindicación 2: Una composición farmacéutica de acuerdo a la reivindicación 1, caracterizada porque dicho al menos un agente activo antiinflamatorio es un esteroide, preferentemente un glucocorticoide corticosteroide. Reivindicación 3: Una composición farmacéutica de acuerdo a la reivindicación 2, caracterizada porque dicho al menos un esteroide se selecciona del grupo que consiste en prednisolona, prednisona, deflazacort, hidrocortisona, metilprednisolona, dexametasona, betametasona, triamcinolona, beclometasona, acetato de fludrocortisona, acetato de deoxicorticosterona.
ARP130100264A 2012-02-03 2013-01-29 Composicion farmaceutica que combina cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil)-naftalen-2-il-metil]-amonio y al menos un agente activo antiinflamatorio para su uso en tratamiento de distrofia muscular AR089839A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2012/000040 WO2013114413A1 (en) 2012-02-03 2012-02-03 Diethyl- [6- (4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl) - naphthalen-2-yl-methyl] -ammonium chloride for use in the treatment of muscular dystrophy

Publications (1)

Publication Number Publication Date
AR089839A1 true AR089839A1 (es) 2014-09-17

Family

ID=45992803

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100264A AR089839A1 (es) 2012-02-03 2013-01-29 Composicion farmaceutica que combina cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil)-naftalen-2-il-metil]-amonio y al menos un agente activo antiinflamatorio para su uso en tratamiento de distrofia muscular

Country Status (11)

Country Link
US (2) US9421184B2 (es)
EP (3) EP2809313A1 (es)
JP (2) JP2015512869A (es)
CN (2) CN107007580A (es)
AR (1) AR089839A1 (es)
AU (1) AU2012368818B2 (es)
BR (1) BR112014018975A2 (es)
CA (1) CA2857082C (es)
HK (1) HK1200731A1 (es)
MX (2) MX370451B (es)
WO (1) WO2013114413A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITUB20155193A1 (it) * 2015-11-03 2017-05-03 Italfarmaco Spa Sospensioni orali di Givinostat fisicamente e chimicamente stabili
IT201900003281A1 (it) * 2019-03-06 2020-09-06 Chemi Spa Processo per preparare {6-[(dietilammino)metil]naftalen-2-il}metil [4-(idrossicarbamoil)fenil]carbammato ad elevata purezza
US11918570B2 (en) 2020-04-13 2024-03-05 The Research Foundation For The State University Of New York Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
ITMI20011733A1 (it) * 2001-08-07 2003-02-07 Italfarmaco Spa Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc
US7229963B2 (en) 2001-10-18 2007-06-12 United States of America as represented by the Secretary of the Department of of Health Services, National Institutes of Health Methods of using deacetylase inhibitors to promote cell differentiation and regeneration
FR2847817B1 (fr) 2002-11-28 2006-11-10 Centre Nat Rech Scient Utilisation d'un inhibiteur d'histone deacetylase pour le traitement des dystrophies musculaires
ITMI20030063A1 (it) 2003-01-17 2004-07-18 Italfarmaco Spa Cloridrato monoidrato dell'estere (6-dietilamminometil-naftalen-2-il)metilico dell'acido (4-idrossicarbammoil-fenil)carbammico.
FR2898274B1 (fr) 2006-03-07 2008-10-03 Sod Conseils Rech Applic Composition contenant des derives d'amidine ou de carboxamide et des steroides a titre de medicament
WO2008101121A2 (en) * 2007-02-14 2008-08-21 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to promoter regulation by muc1 and klf proteins
CA2700058A1 (en) * 2007-09-19 2009-03-26 4Sc Ag Novel tetrahydrofusedpyridines
IT1396915B1 (it) 2009-10-23 2012-12-20 Italfarmaco Spa Dietil-[6-(4-idrossicarbamoil-fenil-carbamoilossimetil)-naftalen-2-il-metil]-ammonio cloruro ed altri derivati della n-idrossi-benzammide per l'uso nel trattamento di infezioni da hiv.
IT1397912B1 (it) * 2010-01-28 2013-02-04 Chemi Spa Nuovo polimorfo dell'estere 6-dietilamminometil-2-naftilico dell'acido 4-idrossicarbamoil-fenil-carbammico cloridrato.
US8217079B2 (en) * 2010-03-26 2012-07-10 Italfarmaco Spa Method for treating Philadelphia-negative myeloproliferative syndromes
WO2011127482A2 (en) * 2010-04-09 2011-10-13 The Salk Institute For Biological Studies Modulation of histone deacetylases for the treatment of metabolic disease, methods and compositions related thereto

Also Published As

Publication number Publication date
EP3858340A1 (en) 2021-08-04
CA2857082C (en) 2019-07-09
AU2012368818A1 (en) 2014-08-21
CN107007580A (zh) 2017-08-04
MX2014009049A (es) 2014-11-25
US9421184B2 (en) 2016-08-23
MX370451B (es) 2019-12-13
WO2013114413A1 (en) 2013-08-08
JP6502876B2 (ja) 2019-04-17
EP2809313A1 (en) 2014-12-10
BR112014018975A2 (pt) 2018-05-08
CA2857082A1 (en) 2013-08-08
MX349767B (es) 2017-08-11
CN104093403A (zh) 2014-10-08
US20160346243A1 (en) 2016-12-01
AU2012368818A2 (en) 2014-08-28
HK1200731A1 (en) 2015-08-14
US9867799B2 (en) 2018-01-16
AU2012368818B2 (en) 2017-11-16
JP2016128504A (ja) 2016-07-14
EP3871669A1 (en) 2021-09-01
JP2015512869A (ja) 2015-04-30
US20140370089A1 (en) 2014-12-18

Similar Documents

Publication Publication Date Title
ECSP21001547A (es) Formulación farmacéutica de odevixibat
RS53329B (en) PROCEDURE AND MIXTURE FOR TREATMENT OF INFLAMMATORY DISORDERS
TR201817995T4 (tr) Nöroakti̇f steroi̇dler ve kullanim yöntemleri̇
JP2012532889A5 (es)
MX2018011706A (es) Composicion farmaceutica de hormona esteroide.
BR112014027681A2 (pt) preparações de agentes terapêuticos hidrofóbicos, métodos de fabricação e uso dos mesmos
BR112016021023A8 (pt) composições de corticosteroides tópicos
MX2017015990A (es) Composiciones topicas que comprenden un corticosteroide y un retinoide para tratar psoriasis.
PH12017500239A1 (en) Abiraterone acetate formulation and methods of use
CR20190433A (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
HRP20201307T1 (hr) Upotreba reslizumaba za liječenje umjerene do ozbiljne eozinofilne astme
CL2019001447A1 (es) Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos.
MX2018006800A (es) Composicion farmaceutica.
BR112015024234A2 (pt) composição de liberação sustentada injetável e método para o uso da mesma para tratar inflamação em articulações e dor associada com a mesma
PE20200444A1 (es) Terapia de combinacion para cancer de prostata
PE20180489A1 (es) Soluciones de esteroide neuroactivo y sus metodos de uso
AR089839A1 (es) Composicion farmaceutica que combina cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil)-naftalen-2-il-metil]-amonio y al menos un agente activo antiinflamatorio para su uso en tratamiento de distrofia muscular
MX2023006235A (es) Composiciones para administracion de farmacos y metodos de uso de las mismas.
MX2018009514A (es) Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1.
MX2014007300A (es) Composiciones farmaceuticas topicas que comprenden bexaroteno y corticosteroides.
ZA201908404B (en) 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases
AR106330A1 (es) Formulaciones de corticoesteroide para mantener las concentraciones de corticoesteroide en líquido sinovial
JP2015034162A5 (es)
RU2007124549A (ru) Средство, усиливающее действие адренокортикоидов, содержащее аравийскую камедь
JP2017516852A5 (es)

Legal Events

Date Code Title Description
FC Refusal